Alzheimer Clinical Trials

595 recruitingLast updated: July 25, 2026

There are 595 actively recruiting alzheimer clinical trials across 55 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Toronto, Ontario, Canada, Miami, Florida, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Alzheimer Trials at a Glance

595 actively recruiting trials for alzheimer are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Not Applicable with 223 trials, with the heaviest enrollment activity in Toronto, Miami, and New York. Lead sponsors running alzheimer studies include Indiana University, Assistance Publique - Hôpitaux de Paris, and Washington University School of Medicine.

Treatments under study

About Alzheimer Clinical Trials

Looking for clinical trials for Alzheimer? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alzheimer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alzheimer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 595 trials

Recruiting
Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

HealthyMild Cognitive ImpairmentAlzheimer s Disease
National Institute of Mental Health (NIMH)90 enrolled1 locationNCT07169630
Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled148 locationsNCT06159673
Recruiting
Not Applicable

Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes

DementiaDiabetesHypoglycemia+1 more
Indiana University62 enrolled1 locationNCT05643144
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.320 enrolled70 locationsNCT06651567
Recruiting
Phase 3

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Alzheimers Disease
Hoffmann-La Roche80,000 enrolled211 locationsNCT07177352
Recruiting
Phase 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer s Disease
Alnylam Pharmaceuticals50 enrolled13 locationsNCT07214727
Recruiting
Phase 3

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

Alzheimer's Disease (AD)Mild Cognitive Impairment Due to Alzheimer's DiseaseAlzheimer Disease Dementia
University College, London1,200 enrolled2 locationsNCT07724132
Recruiting
Not Applicable

Promoting Physical Activity in Older Hispanic/Latino(a) Adults

Physical InactivitySedentary BehaviorAlzheimer Disease, Protection Against
Kaiser Permanente130 enrolled2 locationsNCT06362824
Recruiting

Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers

Alzheimer DiseaseVascular DementiaMild Cognitive Disorder+2 more
University of Erlangen-Nürnberg Medical School5,000 enrolled12 locationsNCT07721701
Recruiting
Phase 1

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

Alzheimer DiseasePreclinical Alzheimer's Disease
Institute for Molecular Medicine48 enrolled5 locationsNCT07158905
Recruiting
Phase 4

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Alzheimer Disease
Alpha Cognition, Inc150 enrolled5 locationsNCT07633470
Recruiting
Phase 1

A Study of LY3439539 in Participants With Alzheimer's Disease

Alzheimer Disease
Eli Lilly and Company30 enrolled9 locationsNCT07598370
Recruiting

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

Multiple SclerosisAlzheimer DiseaseParkinson Disease+2 more
IRCCS San Raffaele1,050 enrolled1 locationNCT07720765
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Alzheimer s Disease
Bristol-Myers Squibb586 enrolled126 locationsNCT06976203
Recruiting
Not Applicable

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Alzheimer DiseaseAlzheimer Disease, Early OnsetLogopenic Progressive Aphasia (LPA)+5 more
Mayo Clinic60 enrolled1 locationNCT02740634
Recruiting

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression

Cognitive ImpairmentDementiaAlzheimer Disease+2 more
IRCCS San Raffaele2,000 enrolled1 locationNCT07717567
Recruiting

Dominantly Inherited Alzheimer Network (DIAN)

Alzheimer s Disease
Washington University School of Medicine700 enrolled26 locationsNCT00869817
Recruiting
Phase 3

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Alzheimer Disease
Eli Lilly and Company140 enrolled30 locationsNCT07571161
Recruiting
Not Applicable

Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome

CognitionAlzheimer Disease and Related DementiasMobility Disability
Hebrew SeniorLife128 enrolled2 locationsNCT06821568